Internationalization and High-Endization: A Growth Curve Driven by Dual Engines

In North America, the company continues to increase its coverage and breakthroughs in large high-end customer IDN healthcare networks. As of the end of the reporting period, the company has covered 80% of IDN healthcare systems and over 2,700 IDN hospitals in the United States, with nearly 35% of these covered IDN hospitals using two or more of the company’s product portfolios.

At Singapore’s IHH Healthcare Group, the largest private healthcare group in Asia, the Mindray team achieved a full-line product breakthrough in new hospital projects in countries such as Turkey under the group. At CHRISTUS Muguerza, a historically significant Catholic hospital group in the United States and Latin America, Mindray won a project for 2,200 infusion pumps in the group’s Latin American region. At Medanta, one of the largest private hospital groups in northern India, Mindray’s integrated solution, including device interoperability, was fully implemented.

In the first half of the year, Mindray Medical’s international in vitro diagnostics business achieved double-digit year-on-year growth, with international chemiluminescence business growing over 20%. During the reporting period, the company broke through over 160 new high-end customers and achieved横向突破 (horizontal breakthroughs) with over 50 existing high-end customers, including nearly 30 third-party连锁 laboratories. The momentum of batch breakthroughs in overseas连锁 laboratories for the in vitro diagnostics business continues.

The announcement shows that during the reporting period, Mindray Medical continued to strengthen its support for the local platform capabilities of its international in vitro diagnostics business, including production manufacturing, logistics distribution, clinical support, and IT services. Currently, the company has localized production projects in 14 countries worldwide, with 11 projects already initiated, most of which involve in vitro diagnostics products. Benefiting from this, the penetration rate of Mindray Medical’s overseas medium- to large-sample-size customers continues to accelerate, leading to the sales installation of 13 sets of the MT 8000 fully automated laboratory intelligent流水线. With the future sales expansion of the MT 8000 fully automated laboratory intelligent流水线 overseas, the international in vitro diagnostics business is expected to maintain its rapid growth trend.

In the life information and support business, the international portion of Mindray Medical’s business further increased to 67% of the entire business line’s revenue. During the reporting period, the company broke through over 100 new high-end customers and achieved横向突破 (horizontal breakthroughs) with nearly 390 existing high-end customers for more products.

In the medical imaging field, the international portion of Mindray Medical’s business further increased to 62% of the entire business line’s revenue. The ultra-high-end ultrasound series achieved nearly RMB 400 million in revenue,接近去年全年 (approaching last year’s full-year revenue). During the reporting period, the company broke through 50 new high-end customers and achieved横向突破 (horizontal breakthroughs) with 130 high-end customers for more products.